Thyroid Cancer and NSAIDs: A Pooled Analysis
Principal Investigator
Name
Naris Nilubol
Degrees
MD
Institution
NCI, CCR, EOB
Position Title
Endocrine Oncology Surgery Fellow
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-1
Initial CDAS Request Approval
Nov 2, 2012
Title
Thyroid Cancer and NSAIDs: A Pooled Analysis
Summary
Thyroid cancer is the most common endocrine malignancy and is one of the fastest growing cancers diagnosed in the U.S. The incidence of thyroid cancer has been increasing over the past three decades. For instance, between 1995 and 2005, the incidence of thyroid cancer has increased 98% in the US. As the incidence of thyroid malignancy rises, preventive medicine and risk reduction becomes paramount. Cyclooxygenase-2 (COX-2) has been closely associated with tumor growth and metastasis in a number of cancers such as lung, breast, colorectal, and cervical cancer. Several studies have demonstrated an overexpression of COX-2 messenger RNA and protein in papillary thyroid cancer (PTC), compared to benign and non-cancerous tissue. In addition, the expression of COX-2 is associated with older age, lymph node metastasis, and advanced stage in patients with thyroid cancer.
Although preclinical study suggests that COX-2 inhibitor significantly reduces the migration and invasion of TPC cell lines, only few patients with medical refractory, metastatic thyroid cancer and strongly positive tumor stain for COX-2 were benefited from COX-2 inhibitor. While the evidence strongly supports the chemopreventive effect of NSAIDs in colorectal cancer, there is no population-based study that addresses the chemopreventive effect of NSAIDs in thyroid cancer. We hypothesize that the incidence of thyroid cancer would be lower in population that chronically consume NSAIDs and the recurrence rate of thyroid cancer may be lower in those who use NSAIDs.
In order to validate our hypothesis, the data from the prospective cohorts of the NIH-AARP Diet and Health Study (NIH-AARP), the U.S. Radiologic Technologists Study (USRT), and The Prostate, Lung, Colorectal, and Ovarian cancer screening Trial will be used to assess thyroid cancer incidence and recurrence in patients consuming NSAIDs chronically.
Although preclinical study suggests that COX-2 inhibitor significantly reduces the migration and invasion of TPC cell lines, only few patients with medical refractory, metastatic thyroid cancer and strongly positive tumor stain for COX-2 were benefited from COX-2 inhibitor. While the evidence strongly supports the chemopreventive effect of NSAIDs in colorectal cancer, there is no population-based study that addresses the chemopreventive effect of NSAIDs in thyroid cancer. We hypothesize that the incidence of thyroid cancer would be lower in population that chronically consume NSAIDs and the recurrence rate of thyroid cancer may be lower in those who use NSAIDs.
In order to validate our hypothesis, the data from the prospective cohorts of the NIH-AARP Diet and Health Study (NIH-AARP), the U.S. Radiologic Technologists Study (USRT), and The Prostate, Lung, Colorectal, and Ovarian cancer screening Trial will be used to assess thyroid cancer incidence and recurrence in patients consuming NSAIDs chronically.
Aims
The primary aim of the study is to evaluate the role of NSAIDs for chemoprevention of thyroid cancer in a large population-based cohort. The secondary objective is to assess whether consumption of NSAIDs would decrease the risk of tumor recurrence in patients with thyroid cancer.
Collaborators
Dr. Martha Linet, NIH/NCI
Dr. Cari Kitahara, NIH/NCI
Dr. Yikyung Park, NIH/NCI
Dr. Electron Kebebew, NIH/NCI
Dr. Dhaval Patel, NIH/NCI